Nonprofessional APCs from Exogenous NY-ESO-1 Polypeptides by Cross-Presentation of HLA Class I Epitopes

[1]  Yao-Tseng Chen,et al.  CD8+ T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[2]  I. Mellman,et al.  Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[3]  S. H. van der Burg,et al.  Established Human Papillomavirus Type 16-Expressing Tumors Are Effectively Eradicated Following Vaccination with Long Peptides1 , 2002, The Journal of Immunology.

[4]  J. Sidney,et al.  Generation of NY-ESO-1-specific CD4+ and CD8+ T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design. , 2002, Cancer research.

[5]  Danila Valmori,et al.  Proteasome-Assisted Identification of a SSX-2-Derived Epitope Recognized by Tumor-Reactive CTL Infiltrating Metastatic Melanoma1 , 2002, The Journal of Immunology.

[6]  P. Srivastava,et al.  Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. , 2002, Annual review of immunology.

[7]  V. Brusic,et al.  NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells. , 2002, Cancer research.

[8]  W. Heath,et al.  Cross-presentation in viral immunity and self-tolerance , 2001, Nature Reviews Immunology.

[9]  A. Suhrbier,et al.  Cytotoxic T cell polyepitope vaccines delivered by ISCOMs. , 2001, Vaccine.

[10]  T. Luft,et al.  Exogenous Peptides Presented by Transporter Associated with Antigen Processing (TAP)-Deficient and TAP-Competent Cells: Intracellular Loading and Kinetics of Presentation1 , 2001, The Journal of Immunology.

[11]  W. Mcclements,et al.  A simple and efficient method for the monitoring of antigen-specific T cell responses using peptide pool arrays in a modified ELISpot assay. , 2001, Journal of immunological methods.

[12]  S. Rosenberg,et al.  CD4+ T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: Association with NY-ESO-1 antibody production , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[13]  C. Théry,et al.  The cell biology of antigen presentation in dendritic cells. , 2001, Current opinion in immunology.

[14]  D. Jäger,et al.  Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[15]  V. Cerundolo,et al.  Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[16]  D. Jäger,et al.  Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[17]  D. Jäger,et al.  Identification of Ny-Eso-1 Epitopes Presented by Human Histocompatibility Antigen (Hla)-Drb4*0101–0103 and Recognized by Cd4+T Lymphocytes of Patients with Ny-Eso-1–Expressing Melanoma , 2000, The Journal of experimental medicine.

[18]  K Eichmann,et al.  The specificity of proteasomes: impact on MHC class I processing and presentation of antigens , 1999, Immunological reviews.

[19]  G. Eberl,et al.  Extracellular processing and presentation of a 69-mer synthetic polypetide to MHC class I-restricted T cells. , 1999, Molecular immunology.

[20]  J. Schlom,et al.  Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide. , 1998, Journal of immunology.

[21]  Lloyd J. Old,et al.  A Survey of the Humoral Immune Response of Cancer Patients to a Panel of Human Tumor Antigens , 1998, The Journal of experimental medicine.

[22]  C. Melief,et al.  Specific T Helper Cell Requirement for Optimal Induction of Cytotoxic T Lymphocytes against Major Histocompatibility Complex Class II Negative Tumors , 1998, The Journal of experimental medicine.

[23]  D. Jäger,et al.  Simultaneous Humoral and Cellular Immune Response against Cancer–Testis Antigen NY-ESO-1: Definition of Human Histocompatibility Leukocyte Antigen (HLA)-A2–binding Peptide Epitopes , 1998, The Journal of experimental medicine.

[24]  A. Goldberg,et al.  Lactacystin and clasto-Lactacystin β-Lactone Modify Multiple Proteasome β-Subunits and Inhibit Intracellular Protein Degradation and Major Histocompatibility Complex Class I Antigen Presentation* , 1997, The Journal of Biological Chemistry.

[25]  Yao-Tseng Chen,et al.  A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[26]  P. Cresswell,et al.  The protease inhibitor, N-acetyl-L-leucyl-L-leucyl-leucyl-L- norleucinal, decreases the pool of major histocompatibility complex class I-binding peptides and inhibits peptide trimming in the endoplasmic reticulum , 1996, The Journal of experimental medicine.

[27]  M. Kovacsovics-Bankowski,et al.  A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules , 1995, Science.

[28]  R. K. Bright,et al.  Immunization of BALB/c mice with recombinant simian virus 40 large tumor antigen induces antibody-dependent cell-mediated cytotoxicity against simian virus 40-transformed cells. An antibody-based mechanism for tumor immunity. , 1994, Journal of immunology.

[29]  J. Berzofsky,et al.  A mutant p53 tumor suppressor protein is a target for peptide-induced CD8+ cytotoxic T-cells. , 1993, Cancer research.

[30]  L. Rénia,et al.  In vitro activity of CD4+ and CD8+ T lymphocytes from mice immunized with a synthetic malaria peptide. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[31]  E. Unanue,et al.  Decrease in macrophage antigen catabolism caused by ammonia and chloroquine is associated with inhibition of antigen presentation to T cells. , 1982, Proceedings of the National Academy of Sciences of the United States of America.